'Her2 positive' diaporamas de présentation

HER2 Positive Breast Cancer

HER2 Positive Breast Cancer. Charles E. Geyer, Jr. MD, FACP Professor of Medicine Division of Hematology, Oncology and Palliative Care Virginia Commonwealth University Associate Director of Clinical Research Massey Cancer Center Heme/Onc Fellows Lecture Series November 1, 2016.

941 views • 70 slides

OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT Mediterranean School of Oncology

OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT Mediterranean School of Oncology Rome, March 30, 2012. NEOADJUVANT THERAPY. Lucia Mentuccia Oncologia Medica, Sora. Goals of Neoadjuvant Theapy in Breast Cancer. To improve surgical outcomes and options

1.01k views • 64 slides

Moderator Neil Love, MD

743 views • 62 slides

Optimizing Treatment for Her 2 Positive Metastatic Breast Cancer Patients

Optimizing Treatment for Her 2 Positive Metastatic Breast Cancer Patients. Sunil Verma MD, MSEd, FRCPC Medical Oncologist Chair, Breast Medical Oncology Sunnybrook Odette Cancer Centre Associate Professor, University of Toronto. Her 2 Story Poor Prognostic Marker. Outline.

1.23k views • 58 slides

ASCO 2012: Breast Cancer Updates

1.06k views • 57 slides

Medical Oncology Training Program Resident Teaching Friday January 7th, 2011 @ PMH, 5-223

Medical Oncology Training Program Resident Teaching Friday January 7th, 2011 @ PMH, 5-223. Locally Advanced and Inflammatory Breast Cancer. Eitan Amir Medical Oncology Princess Margaret Hospital. Surgical oncology Who to send for preoperative therapy? Role of breast conservation

809 views • 57 slides

Key Issues in the Management of Metastatic Breast Cancer

Case 2 (HER2 positive), v5 - July 3, 2009 - to Abraxis Medical. Key Issues in the Management of Metastatic Breast Cancer. Case. First-Line Treatment of HER2-Positive ER-Negative Metastatic Breast Cancer. Case: History. 47-year-old woman with invasive ductal carcinoma 2.0 cm Node negative

590 views • 40 slides

FDA or NOT? Not All LDTs are Alike

389 views • 38 slides

The HER Superfamily of Receptors and Related Pathways in Gastroesophageal Cancers

The HER Superfamily of Receptors and Related Pathways in Gastroesophageal Cancers. AKA: ToGA: The starting point. Jordan Berlin, M.D. Ingram Associate Professor of Medicine Vanderbilt-Ingram Cancer Center. Disclosures. For this talk Advisory board and research support: Roche/Genentech

489 views • 33 slides

Current Patterns of Care in Breast Cancer: Use of Adjuvant Trastuzumab

423 views • 14 slides

Innovation ADC Therapy for Breast Cancer with Remission Rate over 50%

The DS-8201 is designed with the first three proprietary ADC technologies and is a smart chemotherapy solution. It connects a humanized HER2 ADC antibody to a novel topoisomerase I inhibitor payload through a four-tire ADC linker. Compared to traditional chemotherapy, it can target and deliver chemotherapy within cancer cells, thereby reducing systemic exposure to cytotoxic payload (or chemotherapy). Learn more about ADC at https://www.creative-biolabs.com/resource/adc/pdf/com/downloads/HER2-ADC-preparation-and-potency-evaluation-Creative-Biolabs.pdf

157 views • 10 slides

Baselga J et al. Proc SABCS 2012; Abstract S5-1.

Biomarker Analyses in CLEOPATRA: A Phase III , Placebo-Controlled Study of Pertuzumab in HER2 -Positive, First-Line Metastatic Breast Cancer (MBC). Baselga J et al. Proc SABCS 2012; Abstract S5-1. Background.

294 views • 9 slides

358 views • 6 slides

IHC Tests Explained In Simple Words

IHC, or ImmunoHistoChemistry, is a staining process that is specially performed on fresh or frozen breast cancer tissue which gets removed during biopsy. visit https://immunostaining.info

28 views • 2 slides